Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for prevention of chemotherapy-induced neuropathy in breast cancer
IRCT2016050227711N1Phase 2Completed
- Sponsor
- Motamed Cancer Institute
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of duloxetine in chemotherapy-induced peripheral neuropathy (CIPN) and breast cancer, sponsored by Motamed Cancer Institute. Started Jul 2016; status: completed.
02
Drugs
duloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)breast cancer
Beyond the preview
Go deeper on IRCT2016050227711N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016050227711N1.